Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $66.00 Consensus Price Target from Analysts

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has earned an average rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $66.00.

AMPH has been the topic of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price on the stock. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Finally, Piper Sandler restated an “overweight” rating and set a $71.00 target price on shares of Amphastar Pharmaceuticals in a research report on Thursday.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $40.00 on Thursday. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 13.84, a price-to-earnings-growth ratio of 0.83 and a beta of 0.82. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. The business has a fifty day moving average of $41.61 and a 200 day moving average of $47.85. Amphastar Pharmaceuticals has a 1 year low of $38.43 and a 1 year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.20. The company had revenue of $171.84 million during the quarter, compared to analyst estimates of $171.13 million. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. As a group, research analysts expect that Amphastar Pharmaceuticals will post 3.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at $3,851,635.79. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares of the company’s stock, valued at $3,246,132.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $3,851,635.79. The disclosure for this sale can be found here. Insiders sold a total of 8,096 shares of company stock worth $335,259 over the last 90 days. Corporate insiders own 27.10% of the company’s stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. TD Asset Management Inc raised its holdings in Amphastar Pharmaceuticals by 449.0% during the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after purchasing an additional 649,001 shares in the last quarter. Epoch Investment Partners Inc. raised its holdings in Amphastar Pharmaceuticals by 348.7% during the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after purchasing an additional 460,473 shares in the last quarter. Boone Capital Management LLC purchased a new position in Amphastar Pharmaceuticals during the fourth quarter worth about $24,740,000. Victory Capital Management Inc. raised its holdings in Amphastar Pharmaceuticals by 870.9% during the fourth quarter. Victory Capital Management Inc. now owns 237,474 shares of the company’s stock worth $14,688,000 after purchasing an additional 213,014 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Amphastar Pharmaceuticals by 44.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company’s stock worth $25,518,000 after purchasing an additional 171,642 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.